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Abstract
Background: In Europe, extracts from Viscum album (VA-E), the European white-berry mistletoe,
are widely used to treat patients with cancer.
Methods: We searched several databases such as Cochrane, EMBASE, NCCAM, NLM, DIMDI,
CAMbase, and Medline. Inclusion criteria were controlled clinical studies on parameters associated
with survival in cancer patients treated with Iscador. Outcome data were extracted as they were
given in the publication, and expressed as hazard ratios (HR), their logarithm, and the respective
standard errors using standard formulas.
Results: We found 49 publications on the clinical effects of Iscador usage on survival of cancer
patients which met our criteria. Among them, 41 studies and strata provided enough data to
extract hazard ratios (HR) and their standard errors (Iscador versus no extra treatment). The
majority of studies reported positive effects in favour of the Iscador application. Heterogeneity of
study results was moderate (I2 = 38.3%, p < 0.0001). The funnel plots were considerably skewed,
indicating a publication bias, a notion which is corroborated by statistical means (AC = -1.3, CI: -
1.9 to -0.6, p <= 0.0001). A random effect meta-analysis estimated the overall hazard ratio at HR
= 0.59 (CI: 0.53 to 0.66, p < 0.0001). Randomized studies showed less effects than non-randomized
studies (ratio of HRs: 1.24, CI: 0.79 to 1.92, p = 0.35), and matched-pair studies gave significantly
better results than others (ratio of HRs: 0.33; CI: 0.17 to 0.65, p = 0.0012).
Conclusions: Pooled analysis of clinical studies suggests that adjuvant treatment of cancer patients
with the mistletoe extract Iscador is associated with a better survival. Despite obvious limitations,
and strong hints for a publication bias which limits the evidence found in this meta-analysis, one can
not ignore the fact that studies with positive effects of VA-E on survival of cancer patients are
accumulating. Future studies evaluating the effects of Iscador should focus on a transparent design
and description of endpoints in order to provide greater insight into a treatment often being
depreciated as ineffective, but highly valued by cancer patients.
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Complementary and alternative medicine (CAM) has
become increasingly popular over the last decades.
According to Bausell et al. [1], especially patients with
chronic diseases increasingly seek for CAM-therapies.
With a growing amount of health information in the
internet, physicians and therapists and patients are often
not prepared to judge provided information of CAM-
health care approaches properly. Information dissemina-
tion of published evidence about the effectiveness of rem-
edies and therapies therefore forms a necessary basis for
shared-decision making for patients and practitioners.
In Europe, extracts from Viscum album (VA-E), the Euro-
pean white-berry mistletoe, are widely used to treat
patients with cancer, but also with arthrosis, hyperten-
sion, arteriosclerosis, diabetes etc. [2]. Historically, the
intentions of mistletoe uses were manifold and conflict-
ing in several cases (i.e., swellings or tumours, epilepsy,
diseases of spleen and liver, labour-pains, 'weakness of the
heart' and oedema, eczema, ulcers of the feet, burns, and
granulating wounds) [3]. In 1920, mistletoe extracts were
introduced for the first time as a cancer treatment by
Rudolf Steiner (1861-1925) [4], founder of anthroposo-
phy. He recommended a drug extract produced in a com-
plicated manufacturing process combining sap from
mistletoe harvested in the winter and summer [5]. Based
on his recommendations, several Anthroposophic doctors
have treated their cancer patients with these extracts
within the last century, but published - if at all - just some
field reports. Moreover, pharmacological studies on the
suggested anti-tumour effects of were completely lacking.
Meanwhile, clinical evaluations of mistletoe as an adju-
vant cancer treatment have expanded. During the 1960s,
Vester and Nienhaus isolated carcinostatic protein frac-
tions which were recognized later as the cytotoxic visco-
toxins and mistletoe lectins [6]. Recent scientific research
has confirmed the folklore with evidence that mistletoe
extracts (1) induce apoptosis, (2) stimulate immunocom-
petent cells, and (3) protect the DNA of mononuclear
cells (for review see [7,8]). Several experiments using
tumour-bearing animals showed impressive reduction of
tumour growth and/or increased survival with the appli-
cation of mistletoe therapy (for review see [7-9]). The
cytotoxic effects were clearly related to the viscotoxins and
cytotoxic mistletoe lectins, while the immuno-modulat-
ing effects were ascribed to the mistletoe lectins, poly-/oli-
gosaccharides, viscotoxins and several other components
(reviewed in [7-10]).
Results from in vitro studies and animal models indicate
that the direct application of VA-E and their specific com-
ponents (i.e., the cytotoxic mistletoe lectins) results in a
destruction of tumours and metastases, and in an
increased survival of the animals. Thus one may conclude
that the intratumoural injection might be an effective
route of application. Nevertheless, mistletoe extracts are
recommended (and authorized) to be applied subcutane-
ously and not intratumourally.
Moreover, there are several whole plant extracts from Vis-
cum album on the market which differ with respect to the
extraction process and thus relative proportions of their
constituents (i.e., the Anthroposophic manufacturers mix
the mistletoe saps of the summer and winter harvest by
complicated procedures: Abnoba extracts are produced by
aqueous maceration of fresh plant material; Helixor and
Isorel extracts are produced by cold water extraction;
Iscador extracts are produced by fermentation of the plant
material; Iscucin is produced in accordance with the Ger-
man Homeopathic Pharmacopoeia; the phytotherapeutic
companies produce the Eurixor and Lectinol extracts by an
aqueous extraction of the fresh plant material harvested
from poplars during the winter season) [11].
Due to this diversity of mistletoe products and their pro-
portions of pharmacologically relevant constituents, the
interpretation of clinical studies is difficult. Consequently
it is not too surprising that ante ceded reviews on the clin-
ical effects of mistletoe extracts in cancer patients, which
summarizes a mixture of studies with different designs
and plant extracts used, are conflicting in their results [12-
17].
For this review we decided to focus on the survival associ-
ated with the most commonly used mistletoe extracts
which is covered by a large spectrum of published studies,
the fermented plant extract Iscador (WELEDA AG, Switzer-
land). This whole plant extract is produced from fresh
leafy shoots and fruits of the summer and winter harvest,
is rich on mistletoe lectins and viscotoxins [11,18], and is
recommended to be applied 2-3 times per week subcuta-
neously. We intended to determine the effectiveness of the




We searched several databases such as PubMed/Medline,
the Excerpta Medica Database (EMBASE), the Cochrane
Library, database of DIMDI (Deutsches Institut für
Medizinische Dokumentation und Information) and
CAMbase for clinical studies focusing on survival of can-
cer patients using Iscador extracts. Separate search terms
were "Iscador" and "study", "mistletoe" and "study", and
"Viscum" and "study". Finally we asked several experts for
gray literature not listed in the above mentioned data-
bases, checked the reference lists of relevant articles and
authors, and contacted the manufacturer of mistletoePage 2 of 9
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February and April 2008.
Selection criteria
Inclusion criteria were controlled clinical studies (at least
historic or literature) on parameters associated with sur-
vival in cancer patients treated with the VA-E Iscador, pub-
lished in English or German language journals. We
excluded field reports, case series, case reports, studies
without any control group, abstracts which proceeded a
full length publication, translations of already published
manuscripts, double publication of similar data (excep-
tion is the presentation of further data), internal reports
and unpublished manuscripts. In a few cases we had to
exclude studies because of the simultaneous usage of the
fermented extract Iscador and the aqueous extract Helixor.
Analysis of data
Two review authors independently assessed trials for
inclusion in the review. They took part in the extraction of
data and assessment of study quality and clinical rele-
vance. Disagreements were resolved by consensus. We
graded the methodological quality of the studies by the
following checklist (rater assessment): Adequate descrip-
tion of the study design (retrospective, prospective, retro-
lective, multicenter study etc.), subject assembly process
(randomization, matched pairs, etc.), comparability of
groups, description of drop outs, allocation concealment
(analysis of concealed treatment allocation was difficult
because most studies did not provide sufficient data to
judge - either there were no statements or information are
at least unclear), description of the intervention (dosage
and duration of VA-E application), description of statisti-
cal analysis, external validity (representative patients, rel-
evant therapeutic concepts, generalization of results).
However, we did not explicitly refer to rating scores such
as the JADAD, because blinding of VA-E application is dif-
ficult and, due to ethical reasons, rejected by several med-
ical doctors. Thus, 2 out of 5 criteria of the JADAD score
were not applicable for these studies; nevertheless, rand-
omization as a criterion was assessed, also dropouts.
The reporting of the results adhered, if possible and
appropriate, to the MOOSE guidelines [19], which
involve recommendation for the description of study
selection, presentation of results (including a table with
descriptive information for each included study), and dis-
cussion of biases, consideration of alternative explana-
tions for observed results etc.
Data extraction
If a trial was found to be eligible, assessments of its meth-
odological quality were done independently by two
reviewers (AB, TO) and recorded on a pre-especially
designed data form together with the basic trial data and
the extracted results. Allocation concealment was assessed
in accordance with the Cochrane guidelines:
A = adequate (telephone randomization or using consec-
utively numbered, sealed, opaque envelopes)
B = uncertainty about the concealment (method of con-
cealment is not known).
C = inadequate (e.g. alternate days, odd/even date of
birth, hospital number)
Disagreements on methodological quality ratings were
discussed by both assessors until they reached a consen-
sus.
Data were independently extracted by two persons (AB,
TO) and independently entered into a data form which
was especially designed for trials on VA-E by a third per-
son (CR). If the data entries differed, both reviewers were
contacted to recheck the publications and were forced to
come to a consensus, which could be reached in all cases.
Data on the following topics were:
* Details of the publication (first author, country,
year, journal)
* Details on the dosage and application of Iscador
* Type, name, dosage and application of the control
therapy/alternative therapies
* Grading and location of cancer
* Age and gender distribution of patients
* Methodological quality of the study (see above)
* Outcome(s): Survival (median survival, overall sur-
vival, 3-, 5- or 10-year survival etc.)
Statistical analysis
All data were separately analyzed for (a) placebo control-
led trials, (b) actively controlled trials, and (c) trials where
patients of the control group received only standard care
but no extra treatment. Control groups where patients
were "insufficiently treated" with the VA-E (i.e., < 3 pack-
ages within several months/years) were counted as having
received no extra treatment. In one study, the patients
received a glycopeptide preparation from sheep spleens
(Polyerga Neu) versus Iscador versus a complex of B-vita-
mins which was regarded as a placebo, but was regarded
as an "alternative therapy" in our analysis. Active controls
used in the studies were interferon alpha2b or interferonPage 3 of 9
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plex, or radiation.
Outcome data were extracted as hazard ratios (HR), their
logarithm, and the respective standard errors. If HRs were
not given, we assumed that the overall survival was expo-
nentially distributed. This allowed us to estimate hazard
ratios, even if only median survival times or survival rates
were given in the publication. HR < 1 indicate superiority
of Iscador, HR > 1 indicate superiority of the control con-
dition.
The association between study size and trial results was
graphically displayed in funnel plots, by plotting HRs on
the horizontal axis (in a logarithmic scale) against their
standard errors - or against the total patient numbers - on
the vertical axis [20]. Funnel plots are adequate instru-
ments to detect small study size effects, including publica-
tion bias. In the absence of bias, results from small studies
should scatter widely at the bottom of the graph, with the
spread narrowing among larger studies. Publication bias
may lead to asymmetrical funnel plots. Moreover, the
asymmetry of the funnel plot was further explored by a
weighted linear regression analysis (meta-regression)
which modelled the log HR as a function of its standard
error [21]. Weights were chosen inversely to the squared
standard error. From this model, the asymmetry coeffi-
cient (AC) was estimated as the slope of the regression
line.
Heterogeneity between trials was assessed by standard χ2-
tests and the I2 coefficient [22] which measures the per-
centage of total variation across studies due to true heter-
ogeneity rather than chance.
Overall estimates of the treatment effect were obtained
from random effects meta-analysis [23]. Additionally,
from meta-regression a predicted HR was obtained for tri-
als with a standard error as small as the smallest observed
standard error of all included trials.
The extent to which study-level variables were associated
with log HRs was investigated by fitting multivariable
meta-regression models. The following variables were
considered: standard error of log HR, tumour localization
(breast, stomach, lung, colon, ovary, corpus, skin yes/no),
randomization (yes/no), matched-pair comparison (yes/
no) - due to the fact that all matched-pair studies were
from the same source.
Results
We found 52 publications on the clinical effects of Iscador
usage on survival of cancer patients (descriptive details
and references in the additional file 1). Some reports
describe data on different sets of patients and/or tumour
stages or localization (strata), or different study designs
within the same report.
As depicted in Figure 1, eight studies citing the same
results twice in different papers and thus were excluded,
four studies were excluded because of the usage of two dif-
ferent mistletoe extracts (Helixor and/or Iscador) which
were not shown separately. Five studies used alternative or
placebo controls (these data were presented independ-
ently), and 35 studies investigated effects of Iscador versus
no extra treatment.
Iscador versus no extra treatment
Forty one strata (i.e., localization, stages, lymph nodes
etc.) found in 22 studies (Figure 1, additional file 1) pro-
vided enough data to extract HRs and their standard
errors. Twelve studies were prospective in design, five were
randomized, and ten had a matched-pair design. Accord-
ing to the nature of the control group, no study was blind.
The oldest study dated back to 1963, the most recent was
published in 2008. The number of patients enrolled var-
ied considerably from 17 to 1,719, overall 3,388 patients
were treated with Iscador and 7,253 patients served as con-
trols. The studies included in this meta-analysis were of
moderate or even poor quality, as indicated by randomi-
zation, matched pair building, blinding, multicenter,
description of dropouts etc. (additional file 1).
As shown in figure 2, the majority of studies reported pos-
itive effects in favour of the Iscador application. Heteroge-
neity of study results was moderate (I2 = 38.3%, p <
0.0001). Two very small studies showed a very huge effect
in favour of Iscador, but even when these two studies were
discarded, the funnel plots were considerably skewed (fig-
ures 3 and 4), a notion which is corroborated by statistical
means (AC = -1.3, CI: -1.9 to -0.6, p < 0.0001).
A random effect meta-analysis estimated the overall haz-
ard ratio at HR = 0.59 (CI: 0.53 to 0.66, p < 0.0001). Sim-
ple meta-regression yielded a predicted HR = 0.74 (CI:
0.66 to 0.82, p < 0.0001). In multivariable meta-regres-
sion tumour localization generally was not significantly
associated with better or worse study outcome (table 1),
but lung cancer studies showed slightly better outcome
than others (ratio of HRs: 0.56, CI: 0.00 to 1.10, p =
0.095). However, randomized studies showed less effects
than non-randomized studies (ratio of HRs: 1.24, CI: 0.79
to 1.92, p = 0.35), and matched-pair studies gave signifi-
cantly better results than others (ratio of HRs: 0.33; CI:
0.17 to 0.65, p = 0.0012).
Iscador versus placebo
A randomized placebo-controlled clinical trial was under-
taken in 224 patients with advanced lung cancer [24].
Here, the patients received a glycol-peptide preparationPage 4 of 9
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ever, there were no differences between median survival
times (9.1 and 9.0 months) could be found.
Iscador versus alternative therapies
Some trials (respectively strata) were identified which
employed an active treatment as a control arm [24-28],
three of them were randomized controlled trials [24-
26,26].
Study sizes ranged from 46 to 227 patients, overall 462
patients were treated with Iscador, 450 patients with the
alternative therapy.
Heterogeneity of study results was moderate and not sta-
tistically significant beyond chance (I2 = 36.6%, p = 0.15).
The funnel plots were not skewed (AC = 0.2, CI: -1.7 to
2.1, p = 0.86).
No treatment effect could be shown in a random effects
meta-analysis (HR = 0.95, CI: 0.81 to 1.12, p = 0.56). Sim-
ilar results were obtained from simple meta-regression
(predicted HR = 0.94, CI: 0.71 to 1.24, p = 0.66). Multi-
variable meta-regression showed that randomized stud-
ies, however, gave significantly worse results than non-
randomized studies (ratio of HRs: 3.20; CI: 1.16 to 8.85,
p = 0.0247).
Iscador versus no treatment
One non-randomized study compared 81 Iscador treated
breast cancer patients with 30 patients who received an
insufficient treatment (< 4 Iscador) packages within 5
years) which was assigned as "no treatment" [29].
Response rates were 74% and 46% respectively, which can
be translated into a HR = 0.39 (CI: 0.20 to 0.77; p =
0.0068).
Discussion
In this meta-analysis, we investigated the effect of Iscador
on the survival rates of cancer patients. We were able to
demonstrate that adjuvant treatment with Iscador was
associated with a significant overall enhancement of sur-
vival rates. In particular, the benefit of Iscador with respect
to survival was clearly seen in matched pair studies, but
notably less in randomized trials. We also identified the
design of the study as a source of variation among the
studies on the survival of cancer patients using a meta-
regression approach.
With the rapid evolution of both surgical and chemother-
apeutical therapies, the question of survival of cancer
patients is extensively debated. While prognosis of some
cancer entities, i.e. recurrent breast cancer, has improved
within the last decades [30], other cancers only tend to be
moderately impressive, i.e. gall bladder cancer [31]. As a
consequence different oncological treatment regimes
were test - and not all of them were convincing. Other
attempts were the application of low-dose chemothera-
peutic regimen in distinct patients, i.e. advanced unresect-
able hepatocellular carcinoma, which were quite effective
without worsening the quality of life of the patients [32].
Thus, more tolerable treatment regimes for cancer or the
combination of conventional chemotherapy with adju-
vant therapies gain more and more attention in the light
of the primary aim to improve the situation of cancer
patients. From that point of view it is worth to mention
that a similar meta-analysis investigated the effects of VA-
E used as an adjuvant in the treatment of cancer patients
showed moderate improvements on quality of life (Büss-
ing et al., in preparation); however, the methodological
quality of these studies was quite heterogeneous.
Quite similar, the studies included in this meta-analysis
were of moderate or even poor quality (additional file 1).
Although studies in this area face a number of unique
challenges and therefore might be difficult to conduct,
most of the studies were on a low level of documentation
quality. In particular in older studies, traceability and
transparency was missing and thus has to be considered
when looking at our results.
The prospect of randomizing patients to an adjuvant mis-
tletoe treatment often raises ethical debates and negatively
impacts the feasibility of studies [33]. Not surprisingly,
the published randomized trials (not only in this area of
research) are often small and consist of a selected patient
populations compared to observational studies [34]. Fur-
Study selection processFigure 1
Study selection process.
papers citing controlled studies
n=52
publication of the same results twice
n=8
usage of 2 different mistletoe extracts
n=4
papers citing controlles studies
n=40
no extra traetment alternative / placebo treatment
n=35 n=5
studies with extractable data
n=22
extracted strata
n=41Page 5 of 9
(page number not for citation purposes)
BMC Cancer 2009, 9:451 http://www.biomedcentral.com/1471-2407/9/451thermore, due to limited resources, a properly conducted
long-term follow-up in survival is often omitted.
Although the benefit of adjuvant mistletoe treatment has
been demonstrated in some randomized and observa-
tional studies, a comprehensive meta-analytical approach
like the present one has not been previously conducted. In
2003, Ernst et al. [12]published a systematic review on
randomized clinical trials (RCTs) and stated that "statisti-
cal pooling was not possible because of the heterogeneity
of the primary studies. Therefore a narrative systematic
review was conducted." We can confirm the heterogeneity
of studies on the clinical effects of VA-E, but nevertheless
were able to extract data from 41 studies which provided
enough data to calculate HRs and their standard errors.
Ernst et al. [12] stated that the weaker studies implied ben-
efits of VA-E, particularly in terms of quality of life, while
none of the methodologically stronger studies were able
to verify a benefit with respect to survival or quality of life.
A Cochrane Review of Horneber et al. [13] published in
2008 analyzed RCTs on various mistletoe extract prepara-
tions. The authors found weak evidence from RCTs that
VA-E application impacts the survival of cancer patients,
but that it could be effective with respective to quality of
life during chemotherapy for breast cancer. In contrast,
Kienle and Kiene provided a different point of view
[15,16]. In their systematic review of RCTs from 2003 they
identified 23 studies which met their inclusion/exclusion
criteria [15]. Most of these studies reported statistically
significant positive outcomes (or at least positive trends)
for survival or tumour remission and quality of life, while
several studies reported no effect on survival, recurrence,
remission and QOL; just one study showed a negative
trend for disease-free-survival [15]. Also Kienle et al.
agreed that the methodological quality of several studies
was "far below the standard that is today regarded as opti-
mal or necessary" [15]. In 2007, Kienle and Kiene [16]
published a systematic review of prospective clinical trials
on Anthroposophic mistletoe extracts and identified 16
randomized and 9 non-randomized trials. Among them,
8 of 17 trials stated a significant benefit in favour of the
VA-E with respect to survival; remission of tumour and
malignant effusion in 2 of 4 controlled trials; for quality
of life in 3 of 5 studies, and for quality of life and reduc-
tion of side effects of cytoreductive therapies in 5 of 7 tri-
als [16]. They concluded that the best evidence for efficacy
of VA-E exists for improvement of quality of life and
reduction of side effects of cytotoxic therapies, while the
survival benefit was a matter of critique [16].
Methodological quality of studies on the clinical effects of
VA-E has improved over the last years; however, it is not
surprising that particularly the older studies did not meet
the current methodological standards. Indeed, most of the
identified studies did not report data on compliance and
completeness of follow up, intention to treat analysis was
rarely mentioned, clear description of Iscador usage (dura-
tion, dosage) was reported in just a few cases, etc. For this
analysis we did not judge RCTs as methodological 'better'
that non-randomized; each methodological design has its
unique weakness. It can not be ignored that results from
RCTs, despite of their higher internal validity, often have
a lower external validity. Particularly the studies of Gros-
sarth-Maticek [35-43] tried to address this problem and
used a mixed design, i.e. they combined a randomized
matched-pair study with a non-randomized matched pair
Standardized treatment effects (HR and CI) of Iscador versus s  trea ment (the size of circles represents the w ightof the study/s ata in meta-regression)Figure 2
Standardized treatment effects (HR and CI) of 
Iscador versus standard treatment (the size of circles 
represents the weight of the study/strata in meta-
regression). Depicted are the results of 41 strata.Page 6 of 9
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designs exhibited similar results. Although we were aware
that it is quite problematic to separate these nested RCT
from the non-RCT, we nevertheless decided to do so. We
noticed that the survival observed in randomized studies
was lower than in the non-randomized studies, and that
matched-pair studies gave significantly better results than
others. However, several positive reports (and strata) were
from the same origin [35-43] and thus had the same
methodological problems. These studies had a matched
pair design, either with or without randomization; the
description of the methodology was good, the discussion
of potential bias factors was profound. It is obvious that
the strict matching process significantly affected the
number of patients enrolled in the evaluation (all studies
had sample sizes of <200 subjects). Potential bias factors
which might contribute to the overall positive effects
described in the studies of Grossarth-Maticek et al. [35-
43] were discussed in detail by the authors themselves
[35,39], i.e., selection bias and loose matching, etc. How-
ever, because these studies started in 1973, several rele-
vant study objectives were not available, i.e., exact dates of
first diagnosis, operation, initial and follow up-data
assessments and matching, socio-economic status, social
support, spirituality etc. In these studies, attrition bias was
less important because with the drop out of any study
patient, the matching partner was also excluded and thus
the balance of the groups was not severely affected
[35,39]. Altogether, the internal validity of these study
results was limited by selection bias and confounding.
Moreover, there was no written protocol and no statistical
hypotheses, the sample sizes were in most cases very
small, and no sample size calculation. Another intriguing
fact could be that the non-randomized studies of Grossa-
rth-Maticek's group nevertheless might have a lower exter-
nal validity (generalisability), because the inclusion and
exclusion criteria were not very precise and not all of them
explicitly formulated in advance [35,39]. Moreover, apart
from the matching criteria, there were no explicit proce-
dures for building pairs. The most important fact was
raised by the authors themselves [35,39,43], as they can
not exclude the possibility that preferentially patients
with a good prognosis were enrolled, since patients from
both groups who died shortly after the diagnosis would
not have entered the study.
Limitations
A limitation of this meta-analysis is that the pooled esti-
mates are driven by quite heterogeneous data, although
our estimate of I2 = 38.3% laid below the critical boundary
of 0.5 recommended by Higgins & Thompson [44]). Nev-
ertheless, as already mentioned, it has to be taken into
account that our study pool is a composite of quite differ-
ent studies. As long-term survival by definition can only
be obtained from studies which were conducted a number
Funnel plots with respect to standard errors (the line repre-se ts the regression line fr m met -reg ession)igure 3
Funnel plots with respect to standard errors (the line 
represents the regression line from meta-regres-
sion).
Funnel plots with respect to total patient numbersigure 4
Funnel plots with respect to total patient numbers.Page 7 of 9
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treatment techniques which are now considered to be out-
dated. Stratified analysis however suggests that start year
of the study does not affect the pooled effect estimates.
This meta-analysis was restricted to published studies.
Although we tried to be as comprehensive as possible in
our search for studies, the funnel plot is quite skewy and
indicates a significant proportion of publication bias,
which limits the evidence found in this meta-analysis. In
particular the pooled effect estimates are mainly driven by
the study type (i.e., matched-pair design). This phenome-
non has already been recognized in other areas of research
and thus is not due to the specific type of intervention pre-
sented here [45]. Moreover, this does not argue against the
possibility that the patients treated with Iscador had better
survival rates, but should be an indicator to ask for possi-
ble confounder or moderator variables which remain to
be identified.
Conclusions
In conclusion, pooled analysis of clinical studies suggests
that adjuvant treatment of cancer patients with Iscador is
associated with a reduction in mortality rates. Having in
mind the limitations found here, future studies evaluating
the effects of Iscador should continue to address this ques-
tion, with a particular focus on a transparent design and
description of endpoints in order to provide greater
insight into a treatment often being depreciated as ineffec-
tive. The information and considerations from this analy-
sis should be taken seriously not only for a better study
quality but also to provide the best possible care for cancer
patients.
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